Patent US5840507A successfully refreshed from Google Patents.
US5840507A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Methods for cancer prognosis and diagnosis
Assignee: ONCOTECH
•
Filing: 1997-04-11
•
Granted: 1998-11-24
•
Expires: 2017-04-11
Abstract
Abstract The invention provides methods for prognosis, diagnosis, staging and disease progression in human cancer patients related to expression levels of a variety of immunohistochemical and genetic markers associated with poor cancer prognosis, and in particular those markers related to tumor invasiveness, metastasis and spread. The invention also provides methods using a predictive index for prognosis of cancer patients for metastasis, recurrence and relapse of neoplastic disease. The methods of the invention are useful for making clinical decisions on cancer treatment, surveillance and surgical intervention.
Inventors
- 👤 John Fruehauf
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 06:43
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/575; G01N33/5758; G01N2333/00; G01N2333/435; G01N2333/78; Y; Y10; Y10T; Y10T436/00; Y10T436/10; Y10T436/25
Claims Analysis
Total Claims: 5
Claim 1
Independent Claim
327 words
A method for determining the prognosis of cancer patients for metastasis, recurrence and relapse of neoplastic disease comprising the steps of (a) obtaining a tumor sample from a human cancer patient; (b) determining the level of p53 nuclear localization, the level of thrombospondin 1 expression and the extent of microvascularization in the tumor sample by immunohistochemical staining; (c) preparing an index comprising index values of (i) the percentage of cells in the tumor sample that are positive for p53 nuclear localization multiplied by the sum of (one plus the intensity of immunohistochemical staining); (ii) the greatest number of microvessels per 200× magnification field, after a minimum scan of ten fields; and (iii) the percentage of cells in the tumor sample that are positive for thrombospondin 1 expression; wherein the intensity of p53 staining is assigned a value of 0 for staining equal to a negative control, a value of 1 for staining greater than the negative control, a value of 2 for moderate staining intensity which is more than the negative control, but less than the positive control, a value of 3 for staining intensity equal to a positive control, and a value of 4 for staining intensity greater than the positive control; wherein positive p53 nuclear localization is determined by more than 5% of the cells stained at an intensity of 2 or greater; and wherein positive thrombospondin 1 expression is determined by greater than 30 optical density units; (d) weighing the index values of steps (c)(i), (c)(ii) and (c)(iii) on a scale of +1 to -4, to yield weighed values, with low p53 nuclear localization, high thrombospondin 1 expression and low level of microvascularization, each, being scored as +1; and (e) summing the weighed values for p53 nuclear localization, thrombospondin 1 expression and microvascularization; wherein the prognosis for metastasis, recurrence and relapse of neoplastic disease is made when the sum of the weighed values is less than -5 but greater than or equal to -12.
Claim 2
Independent Claim
327 words
A method for determining the prognosis of cancer patients for metastasis, recurrence and relapse of neoplastic disease comprising the steps of (a) obtaining a tumor sample from a human cancer patient; (b) determining the level of p53 nuclear localization, the level of thrombospondin 1 expression and the extent of microvascularization in the tumor sample by immunohistochemical staining; (c) preparing an index comprising index values of (i) the percentage of cells in the tumor sample that are positive for p53 nuclear localization multiplied by the sum of (one plus the intensity of immunohistochemical staining); (ii) the greatest number of microvessels per 200× magnification field, after a minimum scan of ten fields; and (iii) the percentage of cells in the tumor sample that are positive for thrombospondin 1 expression; wherein the intensity of p53 staining is assigned a value of 0 for staining equal to a negative control, a value of 1 for staining greater than the negative control, a value of 2 for moderate staining intensity which is more than the negative control, but less than the positive control, a value of 3 for staining intensity equal to a positive control, and a value of 4 for staining intensity greater than the positive control; wherein positive p53 nuclear localization is determined by more than 5% of the cells stained at an intensity of 2 or greater; and wherein positive thrombospondin 1 expression is determined by greater than 30 optical density units; (d) weighing the index values of steps (c)(i), (c)(ii) and (c)(iii) on a scale of +1 to -4, to yield weighed values, with low p53 nuclear localization, high thrombospondin 1 expression and low level of microvascularization, each, being scored as +1; and (e) summing the weighed values for p53 nuclear localization, thrombospondin 1 expression and microvascularization; wherein the prognosis for metastasis, recurrence and relapse of neoplastic disease is made when the sum of the weighed values is less than -5 but greater than or equal to -12.
Claim 3
Dependent Claim
11 words
The method of claim 1 wherein the cancer is breast cancer.
Claim 4
Dependent Claim
11 words
The method of claim 1 wherein the cancer is prostrate cancer.
Claim 5
Dependent Claim
31 words
The method of claim 1 wherein the prognosis is made when the sum of the weighed values is less than -5, less than -6, less than -7 or less than -8.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-11-23 | 2002-05-25 | 2002-11-24 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-11-23 | 2006-05-25 | 2006-11-24 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-11-23 | 2010-05-25 | 2010-11-24 | $7700.00 | Window Closed / Lapsed |